Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Keryx Pharmaceuticals ( KERX)

Developer of the cancer drug perifosine, Keryx announced recently the completion of enrollment in a phase III colon cancer study, clearing the way for top-line results to be announced before the end of the year.

Year to date performance: -14%

Performance since June 30: -15%

Driehaus Capital Management and Highland Capital Management both opened new positions in Keryx during the quarter, while Balyasny Asset Management added to an existing position that totaled 3.3 million shares at the end of June.

Some small selling of Keryx occurred during the quarter from SAC Capital, Jefferies Group and Citadel Advisors.

If you liked this article you might like

Cancer Drug Stocks: The Winners and Losers From ASCO 2016

5 Stocks Under $10 Set to Soar

8 Stocks Under $10 Making Big Moves Higher

Yellen's Hawkish Claws Rattle Market

Yellen's Hawkish Claws Rattle Market

4 Stocks Under $10 to Trade for Big Breakouts